Scarica l'app Stockscreener
51.54
0.48%
0.2596
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$51.28
Aprire:
$50.442
Volume 24 ore:
2.20M
Relative Volume:
0.19
Capitalizzazione di mercato:
$20.44B
Reddito:
$1.94B
Utile/perdita netta:
$-2.82B
Rapporto P/E:
-7.0975
EPS:
-7.2617
Flusso di cassa netto:
$-2.08B
1 W Prestazione:
-4.46%
1M Prestazione:
+1.99%
6M Prestazione:
+99.09%
1 anno Prestazione:
+50.79%
Intervallo 1D:
$50.34
$52.68
Intervallo di 1 settimana:
$50.19
$53.36
Portata 52W:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
51.53 | 20.34B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
449.94 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
734.73 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
672.40 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
307.25 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.17 | 30.50B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna Inc. stock faces analyst pressure amid patent settlement with Arbutus Biopharma - AD HOC NEWS
Moderna's Spikevax Vaccine: Current Status and Future Prospects in mRNA Technology Evolution - AD HOC NEWS
Lobbying Update: $100,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
Roivant Sciences, Genevant, Arbutus, and Moderna Settle International Patent Litigation – Key Terms and Confidentiality Details - Minichart
Moderna's Spikevax Vaccine: Latest Developments and Future Prospects as of March 2026 - AD HOC NEWS
ABUS: $2.25B Moderna settlement and improved net loss highlight strong 2025 performance - TradingView
ABUS: Secured $950M settlement with Moderna, reduced net loss, and streamlined operations in 2025 - TradingView
Arbutus Biopharma (Nasdaq: ABUS) trims 2025 loss after $2.25B Moderna settlement - Stock Titan
Moderna settlement reshapes Arbutus Biopharma (ABUS) with $950M payout - Stock Titan
Hudson Bay Capital Management LP Lowers Stake in Moderna, Inc. $MRNA - MarketBeat
VIX Spike: Is Moderna Inc a momentum stock2026 Volume & AI Driven Stock Price Forecasts - baoquankhu1.vn
Rate Hike: Should you avoid Moderna Inc stock right nowAnalyst Upgrade & Safe Entry Trade Reports - baoquankhu1.vn
Trade Recap: Is now the right time to enter Moderna Inc2026 Dividend Review & Daily Stock Momentum Reports - baoquankhu1.vn
Moderna Inc. stock faces headwinds amid pipeline delays and FDA vaccine policy shifts - AD HOC NEWS
Aug Macro: Can Moderna Inc continue delivering strong returnsWeekly Stock Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Promising Biotech Stocks To Keep An Eye OnMarch 21st - MarketBeat
Moderna's Spikevax Vaccine Faces Renewed Scrutiny Amid Biotech Sector Momentum and Safety Data Revel - AD HOC NEWS
Moderna to pay about $1 billion to settle Arbutus litigation - MSN
COMMENTARY: An erratic FDA is a threat to innovation - Jefferson City News Tribune
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Therapeutics Sector Q4 Results: Revenue Beats Amid Market Stability - IndexBox
Therapeutics Stocks Q4 Teardown: Moderna (NASDAQ:MRNA) Vs The Rest - Yahoo Finance UK
What triggered Moderna shares' latest price pullback - Traders Union
Why Moderna (MRNA) Is Down 6.4% After Cancer Vaccine Data And Flu Shot’s Expedited FDA Review - Yahoo Finance UK
Pfizer vs Moderna 2026: Pipeline Prospects After Vaccine Sales DropNews and Statistics - IndexBox
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Globe and Mail
Pfizer vs Moderna: Which Pharma Stock Has More Upside? - The Motley Fool
MODERNA, INC. (MRNA) - MSN
Moderna shares see a dip: what is pressuring the stock - Traders Union
Editorial: Erratic FDA is a threat to innovation - The Daily Reflector
Moderna shares see a jump — What is fueling the stock rise - Traders Union
Federal Judge Blocks RFK Jr. Vaccine Policy Shift: Spikevax's Path Forward Stabilized - AD HOC NEWS
Militia Capital Partners LP Sells 49,000 Shares of Moderna, Inc. $MRNA - MarketBeat
Times Opinion: An erratic FDA is a threat to innovation - Chattanooga Times Free Press
Moderna says CEO Stéphane Bancel's 2025 total compensation was $19.9 millionSEC filing - marketscreener.com
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery - FinancialContent
Form DEFA14A Moderna, Inc. - StreetInsider
US Health Secretary Kennedy's vaccine actions and policy positions - marketscreener.com
Moderna, Inc. Trade Ideas — LS:A2N9D9 - TradingView
Moderna Clears Legal Hurdle and Advances Vaccine Pipeline - AD HOC NEWS
Moderna (MRNA) Is Down 5.7% After Costly LNP Settlement And Multi-Pathogen Trial UpdateHas The Bull Case Changed? - simplywall.st
An erratic FDA is a threat to innovation - The Korea Times
Moderna, Inc. Trade Ideas — EUROTLX:4MRNA - TradingView
Moderna (MRNA) Valuation Check As Multi Pathogen mRNA Study Completion And FDA Shifts Draw Fresh Focus - Yahoo Finance
Moderna Impfstoff Spikevax 2025-2026: What Changed This Year - AD HOC NEWS
Moderna Impfstoff (Spikevax) in 2026: Key Updates - AD HOC NEWS
Moderna (MRNA) Valuation Check After Sharp Multi‑Month Share Price Rebound - simplywall.st
Moderna Impfstoff (Spikevax): What Changed in 2026 - AD HOC NEWS
Moderna (MRNA) Declines More Than Market: Some Information for Investors - Yahoo Finance
Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits - JD Supra
Why is Moderna stock down today? - Traders Union
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Moderna Inc Azioni (MRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Mar 02 '26 |
Sale |
52.29 |
13,885 |
726,047 |
59,689 |
0.06%
4.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):